Decreased Ratio of Treg Cells to Th17 Cells Correlates with HBV DNA Suppression in Chronic Hepatitis B Patients Undergoing Entecavir Treatment

PLoS ONE

Volumn 5, Issue 11, 2010, Pages

  Zhang, Ji Yuan ^a   Song, Chun Hui ^a   Shi, Feng ^b   Zhang, Zheng ^a   Fu, Jun Liang ^a   Wang, Fu Sheng ^a  

^a BEIJING 302 HOSPITAL   (China)

^b INSTITUTE OF MICROBIOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ENTECAVIR; HEPATITIS B CORE ANTIGEN; HEPATITIS B(E) ANTIGEN; INTERLEUKIN 17; ALANINE AMINOTRANSFERASE; ANTIVIRUS AGENT; DRUG DERIVATIVE; GUANINE; VIRUS DNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; FEMALE; HEPATITIS B; HUMAN; HUMAN CELL; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; REGULATORY T LYMPHOCYTE; TH17 CELL; VIRUS INHIBITION; VIRUS LOAD; ADOLESCENT; BLOOD; CYTOLOGY; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; FOLLOW UP; GENETICS; HEPATITIS B VIRUS; IMMUNOLOGY; LYMPHOCYTE COUNT; METABOLISM; MIDDLE AGED; MONONUCLEAR CELL; TIME; TREATMENT OUTCOME; VIROLOGY;

HEPATITIS B VIRUS;

ADOLESCENT; ADULT; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; DNA, VIRAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; FOLLOW-UP STUDIES; GUANINE; HEPATITIS B CORE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INTERLEUKIN-17; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; T-LYMPHOCYTES, REGULATORY; TH17 CELLS; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD; YOUNG ADULT;

EID: 78249257780     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0013869     Document Type: Article

References (32)

1. Rehermann B, Nascimbeni M (2005) Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol 5: 215-229.
2. Wang FS (2007) Clinical immune characterization of hepatitis B virus infection and implications for immune intervention: progress and challenges. Hepatol Res 37: S339-346.
3. Wang FS, Zhang Z (2009) Host immunity influences disease progression and antiviral efficacy in humans infected with hepatitis B virus. Expert Rev Gastroenterol Hepatol 3: 499-512.
4. Dienstag JL (2008) Hepatitis B virus infection. N Engl J Med 359: 1486-1500.
5. Huang YW, Chayama K, Tsuge M, Takahashi S, Hatakeyama T, et al. (2010) Differential effects of interferon and lamivudine on serum HBV RNA inhibition in patients with chronic hepatitis B. Antivir Ther 15: 177-184.
6. +regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 22: 531-562.
7. Weaver CT, Hatton RD, Mangan PR, Harrington LE (2007) IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annu Rev Immunol 25: 821-852.
8. Marinos G, Naoumov NV, Williams R (1996) Impact of complete inhibition of viral replication on the cellular immune response in chronic hepatitis B virus infection. Hepatology 24: 991-995.
9. Boni C, Penna A, Ogg GS, Bertoletti A, Pilli M, et al. (2001) Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B: new perspectives for immune therapy. Hepatology 33: 963-971.
10. Stoop JN, van der Molen RG, Baan CC, van der Laan LJ, Kuipers EJ, et al. (2005) Regulatory T cells contribute to the impaired immune response in patients with chronic hepatitis B virus infection. Hepatology 41: 771-778.
11. +regulatory T cells actively influence the antiviral immune response and disease progression in patients with hepatitis B. J Immunol 177: 739-747.
12. Sprengers D, Stoop JN, Binda RS, Kusters JG, Haagmans BL, et al. (2007) Induction of regulatory T-cells and interleukin-10-producing cells in nonresponders to pegylated interferon-alpha therapy for chronic hepatitis B. Antivir Ther 12: 1087-1096.
13. Stoop JN, van der Molen RG, Kuipers EJ, Kusters JG, Janssen HL (2007) Inhibition of viral replication reduces regulatory T cells and enhances the antiviral immune response in chronic hepatitis B. Virology 361: 141-148.
14. +regulatory T cells in patients with hepatitis B virus infection. J Virol 79: 3322-3328.
15. +T cells increase with severity of liver damage in patients with chronic hepatitis B. Hepatology 51: 81-91.
16. Veldhoen M, Hocking RJ, Atkins CJ, Locksley RM, Stockinger B (2006) TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 24: 179-189.
17. Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, et al. (2006) Reciprocal developmental pathways for the generation of pathogenic effector Th17 and regulatory T cells. Nature 441: 235-238.
18. Zhou L, Lopes JE, Chong MM, Ivanov II, Min R, et al. (2008) TGF-betainduced FoxP3 inhibits TH17 cell differentiation by antagonizing RORct function. Nature 453: 236-240.
19. Karino Y, Toyota J, Kumada H, Katano Y, Izumi N, et al. (2010) Efficacy and resistance of entecavir following 3 years of treatment of Japanese patients with lamivudine-refractory chronic hepatitis B. Hepatol Int 4: 414-422.
20. Yokosuka O, Takaguchi K, Fujioka S, Shindo M, Chayama K, et al. (2010) Long-term use of entecavir in nucleoside-naïve Japanese patients with chronic hepatitis B infection. J Hepatol 52: 791-799.
21. Choe WH, Hong SP, Kim BK, Ko SY, Jung YK, et al. (2009) Evolution of hepatitis B virus mutation during entecavir rescue therapy in patients with antiviral resistance to lamivudine and adefovir. Antivir Ther 14: 985-993.
22. Lee JM, Kim HJ, Park JY, Lee CK, Kim do Y, et al. (2009) Rescue monotherapy in lamivudine-resistant hepatitis B e antigen-positive chronic hepatitis B: adefovir versus entecavir. Antivir Ther 14: 705-712.
23. +T cells in acute self-limited hepatitis B virus infection. J Immunol 181: 3741-3744.
24. Boni C, Bertoletti A, Penna A, Cavalli A, Pilli M, et al. (1998) Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B. J Clin Invest 102: 968-975.
25. Boni C, Penna A, Bertoletti A, Lamonaca V, Rapti I, et al. (2003) Transient restoration of anti-viral T cell responses induced by lamivudine therapy in chronic hepatitis B. J Hepatol 39: 595-605.
26. Yasumi Y, Takikawa Y, Endo R, Suzuki K (2007) Interleukin-17 as a new marker of severity of acute hepatic injury. Hepatol Res 37: 248-254.
27. Lemmers A, Moreno C, Gustot T, Maréchal R, Degré D, et al. (2008) The interleukin-17 pathway is involved in human alcoholic liver disease. Hepatology 49: 646-657.
28. Rowan AG, Fletcher JM, Ryan EJ, Moran B, Hegarty JE, et al. (2008) Hepatitis C virus-specific Th17 cells are suppressed by virus-induced TGF-beta. J Immunol 181: 4485-4494.
29. +T cells defines a distinct functional subset with tissue-homing properties. Proc Natl Acad Sci U S A 107: 3006-3011.
30. Leung S, Liu X, Fang L, Chen X, Guo T, et al. (2010) The cytokine milieu in the interplay of pathogenic Th1/Th17 cells and regulatory T cells in autoimmune disease. Cell Mol Immunol 7: 182-189.
31. Oukka M (2007) Interplay between pathogenic Th17 and regulatory T cells. Ann Rheum Dis 66: iii87-90.
32. Weaver CT, Hatton RD (2009) Interplay between the Th17 and Treg cell lineages: a (co-)evolutionary perspective. Nat Rev Immunol 9: 883-889.